Chemidox Clinical Trials

What Chemidox Clinical Trials does

Chemidox Clinical Trials is a US-based, privately-held clinical research site organization headquartered in Lancaster, California. The company operates as a dedicated Phase I–IV clinical trial site, executing drug development studies on behalf of pharmaceutical, biotechnology, and medical device sponsors, as well as contract research organizations (CROs). Its therapeutic coverage spans nine areas: immunology, dermatology, cardiovascular, gastrointestinal, neurology, pain management, psychiatry, endocrinology, and women's health, with current active programs including multiple sclerosis, atopic dermatitis, pediatric asthma/wheezing, COVID-19 boosters, pneumococcal and norovirus vaccines (infants/adults), Pfizer's GBS6 maternal vaccine, and Merck's MK-0616 cholesterol study.

The company's technology stack centers on a cloud-based clinical trial infrastructure built around Electronic Data Capture (EDC) systems for real-time data collection, patient engagement applications supporting virtual visits and e-consent, a cloud-based site network enabling multi-site coordination, big data analytics for trial design and recruitment forecasting, and a dedicated cybersecurity layer for health data protection. It also operates "Chemidox Connect," which appears to be an evolving site network and participant recruitment infrastructure, including an online "Find Your Study" portal that captures inbound participant interest across therapeutic areas.

Commercially, Chemidox is a B2B professional services provider. Revenue is generated per enrolled participant and via study milestone payments negotiated directly with sponsors and CROs on a per-study basis; pricing is not publicly disclosed. GTM is hybrid: enterprise field sales targeting pharma/biotech sponsors and CROs (with dedicated contact channels such as [email protected]), supplemented by a community-led patient recruitment motion driven by healthcare provider referrals, social media, direct email/SMS, and the self-serve participant portal. Named enterprise customers/partners include Pfizer, Moderna, Novartis, Merck, and PRA Health Services. The company employs 11–50 people and is privately held with no disclosed funding rounds or financial data.

Name

Chemidox Clinical Trials

Legal name

Chemidox Clinical Trials Inc

Website

https://chemidox.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Chemidox Clinical Trials is a privately-held US clinical trial site in Lancaster, California, conducting Phase I–IV drug development studies across nine therapeutic areas for pharmaceutical, biotech, and medical device sponsors including Pfizer, Moderna, Novartis, and Merck.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Medical and Diagnostic Laboratories (62151)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Trial Site Operations & Study Coordination (HLAGACAE)

akta.pro secondary industries

Clinical Trial Patient Recruitment & Retention (HLAGACAD), Site Data Management Support (EDC/Source/SDV Readiness) (HLAGACAL), Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

Keywords

• Clinical trial services
• Phase I-IV trials
• Clinical research site
• Patient recruitment services
• Electronic data capture

Headquarters

HQ city

Lancaster

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Trial Services: Chemidox provides clinical trial site services to pharmaceutical, biotechnology, and medical device companies, earning revenue per enrolled participant and through study milestone payments for Phase I-IV trials.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Chemidox Clinical Trials operates as a clinical trial site conducting Phase I-IV drug development studies on behalf of pharmaceutical, biotechnology, and medical device sponsors. The company delivers patient recruitment, on-site study execution, regulatory-compliant data collection, and ongoing participant management across nine therapeutic areas. It supports trial operations with cloud-based Electronic Data Capture systems, digital patient engagement tools, and centralized data analytics.

Product overview

Chemidox Clinical Trials is a clinical research organization operating as a unified clinical trial site rather than a modular software platform. The company manages phases I through IV of drug development in collaboration with pharmaceutical, biotechnology, and medical device companies. Its core offerings consist of clinical trial services across multiple therapeutic areas, including eight named research studies (Multiple Sclerosis Research Study, EAGLE Study, ROCKET Voyager Clinical Trial, COVID-19 Booster Vaccine Studies, Pneumococcal Vaccine Study, Pfizer GBS6 Vaccine Study, Norovirus Vaccine Study, and Cholesterol Research Study MK0616-015). Supporting technology offerings include Electronic Data Capture (EDC) systems and digital health/patient engagement tools. The therapeutic specializations include Immunology, Dermatology, Cardiovascular, Gastrointestinal, Neurology, Pain Management, Psychiatry, Endocrinology, and Women's Health.

Differentiator

Problem solved

Functional benefit

Products and services

• Electronic Data Capture (EDC) Systems Advanced electronic data capture systems enabling real-time data collection and analysis for clinical trials, providing immediate access to critical trial information while maintaining data integrity and regulatory compliance; used by sponsors and CROs contracting with Chemidox for trial execution.
• Digital Health Tools and Patient Engagement Applications Intuitive applications and digital health tools offering trial participants virtual visits, electronic consent forms, and a seamless trial experience; used to support participants enrolled in clinical trials conducted at Chemidox sites and to support sponsor data collection.
• Phase I-IV Clinical Trial Site Services End-to-end clinical trial execution services spanning Phase I through Phase IV, including patient recruitment, study protocol execution, on-site data collection, and regulatory compliance management; offered to pharmaceutical, biotechnology, and medical device sponsors and CROs across nine therapeutic areas.

Quantifiable outcome

• Diverse patient population recruitment enabling representative clinical trial data

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• PfizercoreStrategic or Co-development PartnerChemidox partners with Pfizer to conduct the GBS6 Vaccine Study investigating the efficacy and safety of the GBS6 vaccine in pregnant women. Chemidox's role includes sourcing eligible participants, maintaining clinical trial settings, and ensuring research integrity. The partnership aims to establish immunity in mothers that can be passed to newborns for protection against Group B Streptococcus.
• ModernacoreStrategic or Co-development PartnerChemidox collaborates with Moderna on COVID-19 booster vaccine studies assessing the impact of booster shots against emerging variants. The partnership contributes to global immunity enhancement efforts.
• NovartiscoreStrategic or Co-development PartnerNovartis is listed as a partner company with whom Chemidox collaborates on clinical research studies across various therapeutic areas.
• PRA Health ServicescoreChannel Partner/ Reseller/ DistributorPRA Health Services is referenced as a partner CRO (Contract Research Organization) in the clinical trial ecosystem. CROs manage trial operations on behalf of sponsors and engage sites like Chemidox for trial execution.
• MerckminorStrategic or Co-development PartnerMerck logo appears in the partners/customer section of the website, indicating collaboration on clinical trial activities.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• PRA Health Sciences (now ICON): Global CRO that acquired PRA Health Sciences, Chemidox's named CRO partner. Operates one of the largest site networks worldwide and is the natural upstream referral channel for Chemidox; comparable in that both run Phase I-IV trials for pharma/biotech sponsors.
• IQVIA: Largest global CRO and clinical site network operator, offering Phase I-IV trial services across all major therapeutic areas. Comparable to Chemidox in service offering but vastly larger in scale, sponsor relationships, and geographic reach.
• Medpace Holdings: Mid-to-large full-service CRO running global Phase I-IV trials with strong sponsor relationships across multiple therapeutic areas. Competes with Chemidox for the same pharma/biotech study placements but operates at significantly greater scale.
• Syneos Health: Full-service CRO with site management and patient recruitment capabilities, competing for the same sponsor study awards as Chemidox across therapeutic areas. Broad incumbent with established site network infrastructure.
• Worldwide Clinical Trials: Mid-size global CRO offering Phase I-IV clinical development services across multiple therapeutic areas. Comparable in service mix to Chemidox, but larger and capable of running multi-region programs.
• Parexel International: Large global CRO providing Phase I-IV clinical trial services and site management. Competes for the same big-pharma study contracts as Chemidox, with much broader geographic and operational scale.

Direct peers

• Celerion: Specialty early-phase clinical research organization running Phase I-IIa trials with strong focus on PK/PD and bioequivalence studies. Directly comparable to Chemidox in operating clinical trial sites for pharma/biotech sponsors, though more specialized in early-phase.
• QPS Holdings: Mid-size CRO operating clinical research sites globally with early-phase and bioanalytical capabilities. Direct comparable to Chemidox in business model (site-based clinical research services to pharma/biotech sponsors), at a larger scale.
• Velocity Clinical Research: Multi-site clinical research organization operating integrated trial sites across the US, focused on Phase II-IV trials in multiple therapeutic areas. Direct peer to Chemidox in operating community-based clinical trial sites for pharma/biotech sponsors.
• Clinipace Worldwide: Mid-size CRO providing clinical research services across multiple therapeutic areas for biotech and pharma sponsors. Comparable to Chemidox in service offering and customer base, with broader geographic footprint.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/ChemidoxTrials

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chemidox Clinical Trials